Ocular Therapeutix reported Phase III results showing its investigational Axpaxli (OTX‑TKI) maintained visual acuity better than a low‑dose aflibercept (Eylea) control in wet age‑related macular degeneration, meeting the trial’s superiority endpoint at week 36. The company said it plans to file with the FDA, though investor reaction was muted due to stronger‑than‑expected performance in the control arm. Axpaxli is a tyrosine kinase inhibitor delivered in a bioresorbable intravitreal hydrogel designed for extended durability. Ocular executives highlighted the trial’s Special Protocol Assessment and claimed a clinically meaningful advantage in durability. Analysts noted the market adoption will depend on real‑world durability, label claims, and how retina specialists interpret the control arm performance.